AXLRx Book a callCommission

Mid Specialty · Immunology

Regeneron — Immunology

Regeneron across Immunology: the full competitive set, and the 3 AXLRx reports mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

Commission a Regeneron report

By therapy area

Therapy area All areas ImmunologyPulmonology

Market All United States

AXLRx reports featuring Regeneron — Immunology

CI · Immunology · CI Team · Launch Lead US Atopic Dermatitis Competitive Intelligence Dupilumab's 70% biologic share against JAK step-edits. A two-tier US payer landscape for IL-4Ra biologics and oral JAKs. US · In-Market · Read report → DL · Immunology · CI Team · Launch Lead US Atopic Dermatitis Disease Landscape US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment. US · In-Market · Read report → P&HTA · Immunology · Market Access · Medical Affairs US Atopic Dermatitis Payer & HTA Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected. US · In-Market · Read report →